查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994095

噬菌体市场：2026-2032年全球市场预测（依噬菌体类型、给药途径、製剂、生产流程、应用及最终用户划分）

Bacteriophage Market by Phage Type, Administration Route, Formulation, Production Process, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年噬菌体市场价值为 5,283 万美元，预计到 2026 年将成长至 5,859 万美元，复合年增长率为 5.45%，到 2032 年将达到 7,661 万美元。

主要市场统计数据
基准年 2025 5283万美元
预计年份：2026年 5859万美元
预测年份：2032年 7661万美元
复合年增长率 (%) 5.45%

对噬菌体技术和市场现实进行策略概述，探讨影响研发、监管参与和跨部门部署管道的因素。

噬菌体科学已从微生物学的一个细分领域发展成为一个跨学科平台，涵盖治疗、诊断、农业、食品安全和动物健康等领域。基因组学、製剂科学和可扩展生产平台的最新进展提高了基于噬菌体的解决方案的技术可行性。同时，快速病原体检测和噬菌体分型技术的进步也增强了标靶干预的提案。因此，包括研究机构、医院、食品加工商和农场在内的相关人员正在重新评估噬菌体在更广泛的抗菌作用和生物安全策略中的作用。

识别噬菌体科学、商业化、临床接受度和生产製造方面的变革性变化，这些变化正在推动新的策略转折点。

近年来，一系列变革性因素重新定义了噬菌体从实验室概念转化为实际应用的过程。精准基因组编辑技术的进步使得开发具有客製化宿主范围和有效载荷的重组噬菌体成为可能，从而提高了噬菌体的疗效和商业性价值。同时，快速诊断技术和生物感测器整合技术的进步，透过缩短标靶时间和实现适应性治疗策略，增强了噬菌体产品的临床和农场效用。这些技术的融合正推动着噬菌体产品架构从单一模式转向更模组化、标靶化的方向。

评估 2025 年美国关税对噬菌体供应链、成本结构、国际贸易流动和国内生产的累积影响。

2025年美国的关税政策可能对噬菌体产品的研发和分销的经济效益和物流产生重大影响。进口实验室试剂、专用一次性系统和分析仪器的关税压力可能会增加研究机构和契约製造製造商的上游製程成本。因此，预计筹资策略将转向具有国内生产能力的供应商并实现货源多元化，这就要求企业将关税风险纳入其采购计划和价格谈判中。

关键细分洞察揭示了应用、最终用户、噬菌体分类、给药途径、配方和製造方法如何影响商业化。

细分市场分析阐明了不同应用领域、最终用户、噬菌体类型、给药途径、製剂选择和生产流程在技术要求、应用趋势和经营模式的差异。在应用领域中，噬菌体的应用案例包括农业、动物健康、诊断、食品安全和人类治疗。农业领域着重于植物保护、种子处理和土壤改良，这些领域对稳定性、给药方法和监管证据的要求各不相同。动物健康领域又细分为水产养殖、伴侣动物和畜牧业，这些领域在剂型、给药途径和停药期方面都有显着差异。诊断领域包括生物感测器、病原体检测和噬菌体分型，这些领域都强调灵敏度、速度以及与实验室工作流程的整合。食品安全应用领域着重于乳製品、肉类和农产品的分销管道，需要在加工条件下进行严格的验证。人类治疗领域涵盖皮肤病、消化器官系统、感染疾病和呼吸系统疾病，而感染疾病领域则根据细菌感染疾病和生物膜相关疾病带来的具体挑战进一步细分。

区域洞察重点分析美洲、欧洲、中东和非洲以及亚太地区噬菌体技术市场的不同驱动因素和障碍。

区域趋势对噬菌体解决方案在各市场的开发、监管和应用方式有显着影响。在美洲，监管机构和采购管道强调用于临床准入的可操作管道，私营部门对治疗和农业应用领域都有大量投资。因此，在有报销和采购奖励的地区，噬菌体解决方案的推广应用迅速，但这同时也需要应对复杂的联邦和州级生技药品监管。欧洲、中东和非洲的监管环境则不尽相同。欧洲部分地区拥有完善的框架，以促进临床试验和有条件核准的协调，而该地区不同司法管辖区的监管成熟度则存在差异。这些差异为区域中心的建立创造了机会，这些中心可以支持跨多个司法管辖区的研究和供应链。

深入了解竞争对手和合作伙伴，并专注于塑造噬菌体领域的实力、规模、智慧财产权趋势和策略伙伴关係。

在公司层面，趋势表明，能力累积、策略伙伴关係和智慧财产权组合正在决定企业的竞争地位。拥有强大的研发能力、生产规模和监管合规经验的公司最有利于透过临床和商业管道推广产品。同时，规模小规模、专注于特定领域的生物技术公司和大学衍生企业正在噬菌体工程、递送技术和细分应用领域推动重大创新，从而形成一个从上游发现到下游规模化生产的充满活力的生态系统。

为行业领导者提供切实可行的建议，以加速产品开发、降低商业化风险、优化生产製造以及协调监管和市场策略。

产业领导者应优先考虑整合技术开发、监管策略、生产准备和终端用户参与的综合方法。首先，应投资进行严格的特性分析和稳定性测试，以满足监管申报和采购竞标中预期的证据要件。这有助于减少后期阶段的不确定性，并促进与监管机构的建设性对话。其次，应制定生产蓝图，既包含透过契约製造(CMO) 实现的短期方案，也包含用于建构本地生产能力的中期计划。这种双管齐下的方法有助于应对关税风险和供应中断。

本书详细介绍了用于支持研究结果的可靠调查方法，包括一手和二手调查、专家检验、数据三角测量和情境分析。

本分析所依据的研究采用了一种混合方法，结合了与关键相关人员的对话、详尽的二手资料研究和专家检验。一手资料研究包括对研究机构、契约製造、临床网路、食品加工企业和监管事务部门的领导者进行结构化访谈，以了解实际的限制因素、采购因素和证据要求。这些访谈有助于提出假设，并帮助确定最具影响力的技术和市场动态的优先顺序。

简明扼要的结论整合了有关技术进步、监管趋势、供应链韧性和相关人员。

总之，噬菌体技术正处于一个转折点，科学进步、製造创新、监管调整和市场需求在此交汇融合，为治疗、诊断、农业、食品安全和动物健康领域创造了切实的机会。工程技术的成熟，以及製剂和检测技术的进步，使得更精准、更实用的解决方案成为可能；同时，不断完善的法规结构也在逐步适应噬菌体产品的独特特性。供应链设计和关税环境正在影响生产基地选择和采购方面的战术性决策，凸显了韧性和多元化的战略重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：噬菌体市场：依噬菌体类型划分

  • 改良噬菌体
  • 溶菌噬菌体
  • 温和噬菌体

第九章：噬菌体市场：依给药途径划分

  • 吸入
  • 静脉
  • 口服
  • 外用

第十章：噬菌体市场：依製剂类型划分

  • 胶囊製剂
  • 液体
  • 冷冻干燥製剂

第十一章：噬菌体市场：依生产製程划分

  • 发酵
  • 合成製造

第十二章：噬菌体市场：依应用领域划分

  • 农业
    • 植物保护
    • 种子处理
    • 土壤改良
  • 动物健康
    • 水产养殖
    • 伴侣动物
    • 家畜
  • 诊断
    • 生物修復
    • 病原体检测
    • 噬菌体分型
  • 食品安全
    • 乳製品
    • 肉类
    • 农产品
  • 人类治疗
    • 皮肤科
    • 消化器官系统
    • 感染疾病
      • 细菌感染疾病
      • 生物膜相关
    • 呼吸系统

第十三章：噬菌体市场：依最终用户划分

  • 畜牧场
  • 食品加工公司
  • 医院
  • 研究机构

第十四章 噬菌体市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：噬菌体市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 噬菌体市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国噬菌体市场

第十八章：中国的噬菌体市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Adaptive Phage Therapeutics, Inc.
  • APS Biocontrol Ltd.
  • Armata Pharmaceuticals, Inc.
  • BiomX Ltd.
  • Eliava Biopreparations Ltd.
  • Eligo Bioscience SA
  • EnBIoTix, Inc.
  • Fixed-Phage Limited
  • InnoPhage, Ltd.
  • iNtODEWORLD, Inc.
  • Intralytix, Inc.
  • Locus Biosciences, Inc.
  • Micreos BV
  • NextbIoTics, Inc.
  • Phagelux, Inc.
  • PhagePro, Inc.
  • Phagomed Biopharma GmbH
  • Pherecydes Pharma
  • Proteon Pharmaceuticals SA
  • TechnoPhage SA
Product Code: MRR-1A1A064C03A9

The Bacteriophage Market was valued at USD 52.83 million in 2025 and is projected to grow to USD 58.59 million in 2026, with a CAGR of 5.45%, reaching USD 76.61 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 52.83 million
Estimated Year [2026] USD 58.59 million
Forecast Year [2032] USD 76.61 million
CAGR (%) 5.45%

Strategic introduction to bacteriophage technologies and market realities shaping research, development, regulatory dialogue, and cross-sector adoption pathways

Bacteriophage science has evolved from a niche microbiological discipline into a multidisciplinary platform that intersects therapeutics, diagnostics, agriculture, food safety, and animal health. Recent advances in genomic engineering, formulation science, and scalable production platforms have increased the technical feasibility of phage-based solutions, while parallel improvements in rapid pathogen detection and phage typing have strengthened the value proposition for targeted interventions. Consequently, stakeholders across research institutions, hospitals, food processors, and farms are reassessing where bacteriophages fit within broader antimicrobial stewardship and biosecurity strategies.

At the same time, regulatory frameworks are gradually adapting to accommodate novel biologics that do not conform to traditional small-molecule paradigms. This transition imposes new evidentiary expectations while also opening pathways for conditional and compassionate use in selected settings. In addition, the growth of contract manufacturing and modular fermentation capabilities is lowering the barrier to scale for specialized producers, even as supply chain complexity persists for critical reagents and equipment. Taken together, these structural shifts are reshaping investment priorities, partnership models, and product roadmaps for companies operating in the bacteriophage ecosystem.

This introduction sets the stage for deeper analysis of the technological enablers, market-facing requirements, and cross-sector adoption dynamics that inform strategic decisions today and in the coming planning horizons.

Identifying transformative shifts in bacteriophage science, commercialization, clinical acceptance, and manufacturing that are driving new strategic inflection points

In recent years a cluster of transformative forces has redefined how bacteriophages move from laboratory concepts to deployable solutions. Advances in precision genome editing have enabled engineered phages with tailored host ranges and payloads, increasing both efficacy and commercial attractiveness. Simultaneously, improvements in rapid diagnostics and biosensor integration have strengthened the clinical and on-farm utility of phage products by reducing time-to-target and enabling adaptive treatment strategies. These technological convergences are catalyzing a shift from one-size-fits-all approaches to more modular, targeted product architectures.

Operationally, there is an accelerating emphasis on manufacturing robustness and formulation stability, with encapsulation and lyophilization techniques extending shelf life and enabling broader routes of administration. This capacity expansion is occurring alongside new regulatory dialogues that emphasize safety, traceability, and post-market surveillance, thereby influencing trial design and go-to-market sequencing. Moreover, cross-sector collaborations-linking academic labs, contract manufacturers, and clinical networks-are creating hybrid commercialization models that spread technical risk while concentrating expertise where it matters most.

As a result, incumbents and new entrants must reassess their value propositions, invest selectively in platform capabilities, and build flexible supply chain arrangements to capture emergent opportunities across therapeutics, diagnostics, agriculture, and food safety.

Assessing the cumulative impact of United States tariffs in 2025 on bacteriophage supply chains, cost structures, international trade flows, and domestic production

Tariff policy in the United States during 2025 has the potential to materially influence the economics and logistics of bacteriophage product development and distribution. Tariff-induced cost pressures on imported laboratory reagents, specialized single-use systems, and analytical instrumentation can increase upstream expenses for both research organizations and contract manufacturers. Consequently, procurement strategies are likely to pivot toward suppliers with domestic capacity or diversified sourcing arrangements, and companies will need to incorporate tariff risk into procurement planning and price negotiations.

Beyond direct cost impacts, tariffs can alter cross-border collaboration patterns. When import duties raise the cost of key inputs or finished goods, organizations may accelerate domestic partnerships or invest in local manufacturing to preserve margins and maintain supply continuity. This trend is particularly relevant for high-value, temperature-sensitive formulations where logistics complexity already commands significant attention. Conversely, tariffs can reduce the competitiveness of exported phage-based products, prompting exporters to seek tariff mitigation through product localization, co-manufacturing agreements, or tariff classification strategies that favor lower-duty pathways.

Regulatory and procurement stakeholders should also consider the secondary effects of tariff regimes on innovation pipelines. Increased import costs may incentivize manufacturers to optimize production processes, reduce reliance on single-sourced components, and pursue synthetic or fermentation-based workflows that are less exposed to cross-border tariff volatility. In short, tariffs in 2025 are not simply a near-term cost issue; they are a catalyst for supply chain redesign, strategic localization, and operational resilience that will shape the bacteriophage landscape beyond an immediate fiscal cycle.

Key segmentation insights revealing how applications, end users, phage typologies, administration routes, formulations, and production methods influence commercialization

Segmentation analysis clarifies where technical requirements, adoption dynamics, and commercial models diverge across applications, end users, phage types, administration routes, formulation choices, and production processes. In the application domain, bacteriophage use cases span Agriculture, Animal Health, Diagnostics, Food Safety, and Human Therapeutics. Within Agriculture the emphasis is split among plant protection, seed treatment, and soil amendment, each demanding different stability, delivery, and regulatory evidence profiles. Animal Health subdivides into aquaculture, companion animals, and livestock, where dosage forms, route of administration, and withdrawal considerations vary considerably. Diagnostics includes biosensors, pathogen detection, and phage typing, all of which place a premium on sensitivity, speed, and integration with laboratory workflows. Food Safety applications concentrate on dairy, meat, and produce pathways, requiring robust validation under processing conditions. Human Therapeutics covers dermatology, gastrointestinal, infectious diseases, and respiratory indications, with infectious diseases further differentiated by the specific challenges posed by bacterial infections and biofilm-associated conditions.

Complementing application-focused segmentation, end users encompass animal farms, food processing companies, hospitals, and research institutions, each with distinct procurement cycles, risk tolerances, and operational constraints. Phage typologies-engineered phages, lytic phages, and temperate phages-carry divergent regulatory and IP considerations that affect development timelines and partner selection. Administration routes including inhalation, intravenous, oral, and topical determine formulation strategy and cold chain needs, while formulation formats such as encapsulated, liquid, and lyophilized presentations influence shelf life and logistics. Finally, production choices between fermentation and synthetic manufacturing govern scalability, cost structure, and upstream supply dependencies. Together these segmentation layers create a complex matrix of product design and go-to-market options, and they underscore the importance of aligning technical capabilities with the specific requirements of target applications and end users.

Regional insights highlighting differentiated drivers and barriers across the Americas, Europe Middle East and Africa, and Asia Pacific markets for bacteriophage technologies

Regional dynamics materially affect how bacteriophage solutions are developed, regulated, and adopted across different markets. In the Americas regulatory agencies and procurement channels emphasize pragmatic pathways for clinical access, and there is strong private-sector investment in both therapeutic and agricultural applications. This results in rapid adoption in contexts where reimbursement or procurement incentives exist, but also requires navigation of complex federal and state-level oversight for live biologics. In Europe, Middle East & Africa, the regulatory landscape is heterogeneous: parts of Europe have advanced frameworks that facilitate clinical trial harmonization and conditional approvals, while other jurisdictions within the broader region present varying levels of regulatory maturity. These differences create opportunities for regional hubs that can support multi-jurisdictional studies and supply chains.

In Asia-Pacific, the combination of large agricultural sectors, high-density aquaculture operations, and emerging biotech innovation clusters is driving a distinct set of use cases and commercialization approaches. Regulatory modernization in several Asia-Pacific markets is accelerating local clinical workstreams and domestic manufacturing capacity, which in turn supports faster on-the-ground deployment. Across all regions there is a consistent premium on building local evidence of efficacy and safety, addressing logistics and cold chain challenges, and establishing trusted distribution channels. Moreover, regional procurement policies and tariff environments influence where organizations choose to site production and how they structure cross-border partnerships.

Competitive and collaborative company insights emphasizing capabilities, scale, intellectual property trends, and strategic partnerships shaping the bacteriophage landscape

Company-level dynamics reveal a landscape where capability clusters, strategic partnerships, and IP portfolios determine competitive positioning. Firms that combine robust R&D operations with manufacturing scale and regulatory experience are best positioned to move products into clinical and commercial channels. At the same time, smaller specialized biotechs and academic spinouts contribute critical innovation around phage engineering, delivery technologies, and niche applications, creating a vibrant ecosystem of upstream discovery and downstream scale-up.

Partnership models are particularly important: contract development and manufacturing organizations, diagnostic integrators, and agriculture-focused distributors provide the operational muscle that enables innovators to reach end users. Intellectual property strategies matter not only for protecting engineered constructs but also for securing freedom to operate around manufacturing processes and formulation technologies. Additionally, companies that proactively engage with regulatory agencies and invest in transparent safety and surveillance programs tend to reduce commercialization timelines and build trust with purchasing decision-makers.

Finally, access to capital and the ability to demonstrate reproducible manufacturing and clinical evidence remain critical gating factors. Investors and partners are increasingly looking for demonstrable translational milestones, credible risk mitigation plans, and the operational readiness to scale production while maintaining stringent quality control.

Actionable recommendations for industry leaders to accelerate development, de-risk commercialization, optimize manufacturing, and align regulatory and market strategies

Industry leaders should prioritize an integrated approach that links technology development with regulatory strategy, manufacturing readiness, and end-user engagement. First, invest in rigorous characterization and stability studies that align with anticipated evidence requirements for regulatory submissions and procurement tenders. This reduces later-stage uncertainty and facilitates constructive dialogue with authorities. Second, design manufacturing roadmaps that include both short-term options through contract manufacturing organizations and medium-term plans for localized capacity; such dual-track approaches help manage tariff exposures and supply interruptions.

Third, pursue targeted partnerships that connect discovery teams with distribution channels in hospitals, food processing, and agricultural sectors. These relationships accelerate adoption by embedding phage solutions into existing operational workflows and by generating real-world performance data. Fourth, adopt a modular product architecture that accommodates different administration routes and formulation formats, thereby increasing addressable use cases while streamlining development effort. Finally, build a transparent post-market surveillance framework to monitor efficacy, resistance patterns, and safety, and use that evidence to refine indications, dosing strategies, and messaging to payers and procurement bodies.

Taken together, these recommendations support de-risked commercialization, scalable manufacturing, and credible engagement with regulators and end users, enabling organizations to convert scientific potential into sustained impact.

Robust research methodology detailing primary and secondary approaches, expert validation, data triangulation, and scenario analysis used to underpin findings

The research underpinning this analysis used a mixed-methods approach combining primary stakeholder engagement with exhaustive secondary review and expert validation. Primary research included structured interviews with leaders in research institutions, contract manufacturing, clinical networks, food processing operations, and regulatory affairs to capture real-world constraints, procurement drivers, and evidence expectations. These interviews informed hypothesis generation and helped prioritize the most consequential technology and market dynamics.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, patent filings, and publicly available technical briefs to map technological trajectories and historical precedent. Data triangulation methods were applied to reconcile differing perspectives, and scenario analysis was used to stress-test assumptions about supply chain shocks, regulatory timelines, and adoption velocity. Expert panels provided iterative validation of key findings and guided the construction of strategic recommendations, while methodological transparency was maintained through documented interview protocols, source logs, and a reproducible analytical framework.

This blended methodology ensures the conclusions are grounded in empirical observation, validated by domain experts, and robust to a range of plausible futures, thereby supporting actionable decision-making for executives and investors.

Concise conclusion synthesizing evidence on technological progress, regulatory momentum, supply chain resilience, and strategic imperatives for stakeholders

In conclusion, bacteriophage technologies are at an inflection point where scientific progress, manufacturing innovation, regulatory adaptation, and market demand converge to create tangible opportunities across therapeutics, diagnostics, agriculture, food safety, and animal health. The maturation of engineering techniques, coupled with advances in formulation and detection technologies, enables more precise and deployable solutions, while evolving regulatory frameworks are gradually accommodating the special characteristics of phage-based products. Supply chain design and tariff environments will influence tactical decisions about production siting and sourcing, underscoring the strategic importance of resilience and diversification.

Companies that succeed will be those that align rigorous technical evidence with pragmatic manufacturing plans, proactive regulatory engagement, and deep end-user partnerships. By adopting modular product architectures, investing in demonstrable safety and surveillance programs, and building flexible supply chains, organizations can move from proof-of-concept to routine deployment. Ultimately, the most consequential progress will stem from integrated approaches that convert scientific capability into operationally reliable, economically viable, and clinically or operationally effective solutions for the stakeholders who depend on them.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bacteriophage Market, by Phage Type

  • 8.1. Engineered Phages
  • 8.2. Lytic Phages
  • 8.3. Temperate Phages

9. Bacteriophage Market, by Administration Route

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Topical

10. Bacteriophage Market, by Formulation

  • 10.1. Encapsulated Formulation
  • 10.2. Liquid Formulation
  • 10.3. Lyophilized Formulation

11. Bacteriophage Market, by Production Process

  • 11.1. Fermentation
  • 11.2. Synthetic Manufacturing

12. Bacteriophage Market, by Application

  • 12.1. Agriculture
    • 12.1.1. Plant Protection
    • 12.1.2. Seed Treatment
    • 12.1.3. Soil Amendment
  • 12.2. Animal Health
    • 12.2.1. Aquaculture
    • 12.2.2. Companion Animals
    • 12.2.3. Livestock
  • 12.3. Diagnostics
    • 12.3.1. Biosensors
    • 12.3.2. Pathogen Detection
    • 12.3.3. Phage Typing
  • 12.4. Food Safety
    • 12.4.1. Dairy
    • 12.4.2. Meat
    • 12.4.3. Produce
  • 12.5. Human Therapeutics
    • 12.5.1. Dermatology
    • 12.5.2. Gastrointestinal
    • 12.5.3. Infectious Diseases
      • 12.5.3.1. Bacterial Infections
      • 12.5.3.2. Biofilm Associated
    • 12.5.4. Respiratory

13. Bacteriophage Market, by End User

  • 13.1. Animal Farms
  • 13.2. Food Processing Companies
  • 13.3. Hospitals
  • 13.4. Research Institutions

14. Bacteriophage Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Bacteriophage Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Bacteriophage Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Bacteriophage Market

18. China Bacteriophage Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Adaptive Phage Therapeutics, Inc.
  • 19.6. APS Biocontrol Ltd.
  • 19.7. Armata Pharmaceuticals, Inc.
  • 19.8. BiomX Ltd.
  • 19.9. Eliava Biopreparations Ltd.
  • 19.10. Eligo Bioscience SA
  • 19.11. EnBiotix, Inc.
  • 19.12. Fixed-Phage Limited
  • 19.13. InnoPhage, Ltd.
  • 19.14. iNtODEWORLD, Inc.
  • 19.15. Intralytix, Inc.
  • 19.16. Locus Biosciences, Inc.
  • 19.17. Micreos BV
  • 19.18. Nextbiotics, Inc.
  • 19.19. Phagelux, Inc.
  • 19.20. PhagePro, Inc.
  • 19.21. Phagomed Biopharma GmbH
  • 19.22. Pherecydes Pharma
  • 19.23. Proteon Pharmaceuticals S.A.
  • 19.24. TechnoPhage SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BACTERIOPHAGE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BACTERIOPHAGE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BACTERIOPHAGE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BACTERIOPHAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GCC BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 253. GCC BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. GCC BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 257. GCC BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 258. GCC BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 259. GCC BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 260. GCC BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 262. GCC BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 290. G7 BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 292. G7 BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 293. G7 BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 294. G7 BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. G7 BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 296. G7 BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 297. G7 BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 299. G7 BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 301. G7 BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. NATO BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. NATO BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. NATO BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 305. NATO BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 306. NATO BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 308. NATO BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 309. NATO BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 310. NATO BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 311. NATO BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 312. NATO BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 314. NATO BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)